Status:
ENROLLING_BY_INVITATION
Personalized Brain Stimulation for Cognitive Impairment in Older Adults
Lead Sponsor:
Xuanwu Hospital, Beijing
Conditions:
Alzheimer s Disease
Eligibility:
All Genders
50-90 years
Phase:
NA
Brief Summary
This study aims to develop and test new personalized treatments for older adults with cognitive impairment. Project 1: Create a personalized cognitive training program using computer algorithms to ma...
Detailed Description
This study is designed to improve the treatment and care of older adults with cognitive impairment through three related projects. Project 1: Development of a personalized cognitive training program....
Eligibility Criteria
Inclusion
- Inpatients or outpatients aged 50-90 years;
- Patients diagnosed with amnestic mild cognitive impairment (aMCI) due to AD or mild dementia due to AD, based on the 2018 NIA-AA clinical diagnostic criteria established by the National Institute on Aging and the Alzheimer's Association;
- Neuropsychological assessment showing MMSE scores between 18 and 26, and a CDR score of 0.5 or 1;
- Able to communicate fluently in Chinese (non-illiterate);
- For those currently receiving cholinesterase inhibitor therapy (e.g., donepezil or rivastigmine), the treatment dose must be stable, defined as a fixed dosage administered continuously for at least six weeks, with no adjustment of the medication regimen during the study period;
- Provision of written informed consent.
Exclusion
- Documented history of cerebrovascular stroke, with clear neurological deficits at onset and corresponding responsible lesions on neuroimaging;
- Moderate to severe white matter lesions (Fazekas score 3-6);
- Presence of any cause of consciousness disorder;
- Severe aphasia or motor disability that prevents completion of neuropsychological assessments;
- Current psychiatric disorders;
- History of alcohol dependence, drug addiction, traumatic brain injury, epilepsy, encephalitis, normal-pressure hydrocephalus, or other neurological disorders that may cause cognitive impairment;
- Systemic diseases that may contribute to mild cognitive impairment (e.g., hepatic or renal insufficiency, endocrine disorders, vitamin deficiencies);
- Considered unsuitable for participation by the investigators.
Key Trial Info
Start Date :
May 1 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
November 30 2027
Estimated Enrollment :
460 Patients enrolled
Trial Details
Trial ID
NCT07208734
Start Date
May 1 2024
End Date
November 30 2027
Last Update
October 6 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Xuanwu Hospital, Capital Medical University, Beijing, Beijing 100053
Beijing, Beijing Municipality, China, 100053